Outcome and prognostic factors of low-grade serous ovarian cancer: An observational retrospective study

被引:0
|
作者
Alhusaini, Hamed [1 ]
Badran, Ahmed [1 ,2 ]
Al Juhani, Amal [1 ,3 ]
Alshamsan, Bader [4 ]
Alsagaih, Yasamiyan [5 ]
Alqayidi, Ahmed A. [3 ]
Sheikh, Ali [6 ]
Elhassan, Tusneem [7 ]
Maghfoor, Irfan [1 ]
Elshentenawy, Ayman [1 ,8 ]
Elshenawy, Mahmoud A. [1 ,9 ]
机构
[1] King Faisal Specialist Hosp & Res Ctr, Dept Med Oncol, Makkah Al Mukarramah Rd, Riyadh 11211, Saudi Arabia
[2] Ain Shams Univ, Fac Med, Dept Clin Oncol & Nucl Med, Cairo 11591, Egypt
[3] Secur Forces Hosp, Dept Med, Minist Interior, Riyadh 11481, Saudi Arabia
[4] Qassim Univ, Coll Med, Dept Med, Buraydah 51432, Saudi Arabia
[5] King Salman Specialist Hosp, Dept Med Oncol, Hail 55471, Saudi Arabia
[6] Al Faisal Univ, Coll Med, Riyadh 11533, Saudi Arabia
[7] King Faisal Specialist Hosp & Res Ctr, Oncol Ctr, Riyadh 11211, Saudi Arabia
[8] Cairo Univ, Fac Med, Kasr Al Ainy Ctr Clin Oncol & Nucl Med NEMROCK, Cairo 115621, Egypt
[9] Menoufia Univ, Fac Med, Dept Clin Oncol, Shibin Al Kawm 32511, Egypt
关键词
low-grade serous ovarian cancer; progression-free survival; overall survival; cytoreductive surgery; chemotherapy; hormonal treatment; EPITHELIAL OVARIAN; FALLOPIAN-TUBE; WOMEN; CARCINOMA; PERITONEUM; TUMORS; CLASSIFICATION; THERAPY; DISEASE; OBESITY;
D O I
10.3892/mco.2024.2745
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Low-grade serous ovarian cancer (LGSOC) is a very rare histological subtype of serous ovarian cancer, representing similar to 2% of all epithelial ovarian cancer cases. LGSOC has a better prognosis but a lower response rate to chemotherapy in comparison to high-grade serous ovarian carcinoma (HGSOC). The present study is a retrospective review of the medical records of all patients with histologically proven LGSOC diagnosed and treated in a single institute between January 2003 and December 2019. A total of 23 patients diagnosed with LGSOC and treated at King Faisal Specialist Hospital and Research Center (Riyadh, Saudi Arabia) were identified. The median age at diagnosis was 45.5 years (range, 26-66 years) and the median body mass index was 26.1 (range, 18-43). A total of 21 patients (91.3%) had de novo LGSOC, whereas only 2 patients (8.7%) had LGSOC that had transformed from serous borderline ovarian tumors and recurred. A total of 8 patients (34.8%) were diagnosed with International Federation of Gynecology and Obstetrics stage IV, whereas 3 (13.0%), 3 (13.0%) and 9 (39.1%) were diagnosed with stages I, II and III, respectively. In addition, 10 (43.5%), 5 (21.7%), and 3 (13.0%) patients had complete response, stable disease and partial response statuses after first-line therapy, respectively. At a median follow-up time of 34 months [95% confidence interval (CI), 25.32-42.69], the median progression-free survival (PFS) time was 75.2 months (95% CI, 17.35-133.05) and the median overall survival (OS) time was not reached. In conclusion, LGSOC exhibited better PFS and OS times than HGSOC as compared with data from the literature, and there is the option for systemic treatment (chemotherapy or hormonal therapy). Optimal cytoreduction showed numerically higher, but non-significant, PFS and OS times compared with suboptimal debulking; however, the optimal systemic chemotherapy or hormonal treatment remains controversial.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] SELUMETINIB HAS ACTIVITY IN LOW-GRADE SEROUS OVARIAN CANCER
    不详
    CANCER DISCOVERY, 2013, 3 (02) : 134 - 134
  • [22] Low-grade serous Ovarian Cancer - Fertility Preservation or Hysterectomy?
    Geretto, Magdalena
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (06) : 491 - 491
  • [23] Ki67 expression as a predictor of chemotherapy outcome in low-grade serous ovarian cancer
    Grabowski, Jacek P.
    Martinez Vila, Clara
    Richter, Rolf
    Taube, Eliane
    Plett, Helmut
    Braicu, Elena
    Sehouli, Jalid
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (04) : 498 - 503
  • [24] Low grade serous ovarian cancer: Unpicking drivers of outcome
    Gourley, Charlie
    Hollis, Robert L.
    GYNECOLOGIC ONCOLOGY, 2022, 167 (02) : 137 - 138
  • [25] Management challenges in low-grade serous ovarian cancer with a BRCA mutation
    Sanchez-Lorenzo, Luisa
    Sancho, Lidia
    Iscar, Teresa
    Grisham, Rachel
    Chiva, Luis
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (04) : 631 - 636
  • [26] The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer
    Crane, Erin K.
    Sun, Charlotte C.
    Ramirez, Pedro T.
    Schmeler, Kathleen M.
    Malpica, Anais
    Gershenson, David M.
    GYNECOLOGIC ONCOLOGY, 2015, 136 (01) : 25 - 29
  • [27] Treatment of Recurrent Low-grade Serous Ovarian Cancer With MEK Inhibitors
    Kulkarni, Anjali
    Cooke, Carly
    Fazelzad, Rouhi
    Fung-Kee-Fung, Michael
    May, Taymaa
    Zigras, Tiffany
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (01): : 11 - 16
  • [28] Principles of Treatment for Borderline, Micropapillary Serous, and Low-Grade Ovarian Cancer
    Hacker, Kari E.
    Uppal, Shitanshu
    Johnston, Carolyn
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (09): : 1175 - 1182
  • [29] Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review
    Lazurko, Caitlin
    Linder, Revital
    Pulman, Kate
    Lennox, Genevieve
    Feigenberg, Tomer
    Fazelzad, Rouhi
    May, Taymaa
    Zigras, Tiffany
    CURRENT ONCOLOGY, 2023, 30 (09) : 8159 - 8171
  • [30] Identifying mechanisms of therapeutic resistance in low-grade serous ovarian cancer
    Nobre, Silvana Pedra
    Peplinski, Rebekah
    Schillo, Jacob
    Ulmer, Keely
    Riordan, Jesse
    Dupuy, Adam
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S305 - S305